Shenzhen Chipscreen Biosciences Co

Chipscreen Biosciences released its 2026 interim report, with net profit attributable to the parent company of 71.3806 million yuan. Total operating revenue was 543 million yuan, and net cash inflow from operating activities was 89.3651 million yuan. The latest asset-liability ratio was 44.56 percent, up 0.97 percentage points from the previous quarter. Gross margin was 86.33 percent, down 0.45 percentage points from the same period last year. Return on equity was 2.80 percent. Diluted earnings per share were 0.16 yuan, total asset turnover was 0.13 times, and inventory turnover was 1.20 times. The number of shareholders was 25,600, and the top ten shareholders held 115 million shares, accounting for 25.96 percent of total share capital.

Chipscreen Biosciences released its 2026 interim report. First-half net profit attributable to the parent was 71.38 million yuan, up 141.2% year on year. Operating revenue was 543 million yuan, up 33.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 64.7 million yuan, up 218.4% year on year. Net operating cash flow was 89.37 million yuan, up 44.0% year on year. Second-quarter net profit attributable to the parent was 43.11 million yuan, down 11.6% year on year. Sales of the company's core product Chiglitazar Sodium more than doubled, and two solid-dose production lines in Workshop 8 received the drug GMP compliance inspection notification in the second quarter.

Chipscreen Biosciences announced that the clinical trial application for injectable NW001, co-developed with Chengdu Chipscreen New Domain Biotechnology, for the treatment of advanced malignant tumors, including solid tumors and lymphoma, has received the Acceptance Notice for domestic production drug registration clinical trials issued by the Center for Drug Evaluation of the National Medical Products Administration.

Chipscreen Biosciences' self-developed multi-target protein kinase inhibitor CS43158 tablets clinical trial application has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. The application targets the treatment of acute myeloid leukemia and is an investigational new drug application. If no negative or questioning opinions are received within 60 days after acceptance, the company can proceed with clinical trials according to the submitted protocol. CS43158 is designed to simultaneously cover the driver oncogenic pathways and bypass activation resistance pathways of acute myeloid leukemia, possessing the dual effects of targeting primary driver mutations and overcoming secondary resistance. In the first quarter of 2026, Chipscreen Biosciences achieved revenue of 257 million yuan and a net profit attributable to the parent company of 28.27 million yuan.